Anti-IL13 antibodies and uses thereof
The present invention relates to anti-IL13 antibodies that bind specifically and with high affinity to both glycosylated and non-glycosylated human IL13, does not bind mouse IL13, and neutralize human IL13 activity at an approximate molar ratio of 1:2 (MAb:IL13). The invention also relates to the use of these antibodies in the treatment of IL13-mediated diseases, such as allergic disease, including asthma, allergic asthma, non-allergic (intrinsic) asthma, allergic rhinitis, atopic dermatitis, allergic conjunctivitis, eczema, urticaria, food allergies, chronic obstructive pulmonary disease, ulcerative colitis, RSV infection, uveitis, scleroderma, and osteoporosis.
1. A method for treating allergic rhinitis in a patient, comprising administering to the patient an effective amount of an anti-IL-13 antibody that specifically binds human IL-13, wherein the anti-IL-13 antibody comprises a heavy chain variable region comprising complementarity determining regions CDRH1, CDRH2 and CDRH3 having the amino acid sequences of SEQ ID NO: 117, SEQ ID NO: 123, and SEQ ID NO: 135, respectively; and a light chain variable region comprising complementarity determining regions CDRL1, CDRL2 and CDRL3 having the amino acid sequences of SEQ ID NO: 99, SEQ ID NO: 104, and SEQ ID NO: 115, respectively.
2. The method of claim 1 , wherein the anti-IL-13 antibody comprises a light chain variable region having the amino acid sequence of SEQ ID NO: 142, and a heavy chain variable region having the amino acid sequence of SEQ ID NO: 143.
3. The method of claim 1 , wherein the anti-IL-13 antibody is an IgG1, an IgG2, an IgG3 or an IgG4 antibody.
4. The method of claim 1 , wherein the anti-IL-13 antibody is humanized.
5. A method for treating urticaria in a patient, comprising administering to the patient an effective amount of an anti-IL-13 antibody that specifically binds human IL-13, wherein the anti-IL-13 antibody comprises a heavy chain variable region comprising complementarity determining regions CDRH1, CDRH2 and CDRH3 having the amino acid sequences of SEQ ID NO: 117, SEQ ID NO: 123, and SEQ ID NO: 135, respectively; and a light chain variable region comprising complementarity determining regions CDRL1, CDRL2 and CDRL3 having the amino acid sequences of SEQ ID NO: 99, SEQ ID NO: 104, and SEQ ID NO: 115, respectively.
6. The method of claim 5 , wherein the anti-IL-13 antibody comprises a light chain variable region having the amino acid sequence of SEQ ID NO: 142, and a heavy chain variable region having the amino acid sequence of SEQ ID NO: 143.
7. The method of claim 5 , wherein the anti-IL-13 antibody is an IgG1, an IgG2, an IgG3 or an IgG4 antibody.
8. The method of claim 5 , wherein the anti-IL-13 antibody is humanized.
9. A method for treating scleroderma in a patient, comprising administering to the patient an effective amount of an anti-IL-13 antibody that specifically binds human IL-13, wherein the anti-IL-13 antibody comprises a heavy chain variable region comprising complementarity determining regions CDRH1, CDRH2 and CDRH3 having the amino acid sequences of SEQ ID NO: 117, SEQ ID NO: 123, and SEQ ID NO: 135, respectively; and a light chain variable region comprising complementarity determining regions CDRL1, CDRL2 and CDRL3 having the amino acid sequences of SEQ ID NO: 99, SEQ ID NO: 104, and SEQ ID NO: 115, respectively.
10. The method of claim 9 , wherein the anti-IL-13 antibody comprises a light chain variable region having the amino acid sequence of SEQ ID NO: 142, and a heavy chain variable region having the amino acid sequence of SEQ ID NO: 143.
11. The method of claim 9 , wherein the anti-IL-13 antibody is an IgG1, an IgG2, an IgG3 or an IgG4 antibody.
12. The method of claim 9 , wherein the anti-IL-13 antibody is humanized.